Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Lenalidomide

AEMPS

Immunomodulatory drug (IMiD), thalidomide derivative

ATC code: L04AX04

Updated · Methodology

Indications

A

Multiple myeloma

First line

Foundation component of multiple myeloma therapy per IMWG 2014 and ESMO 2024. In newly diagnosed patients, lenalidomide is in triplet and quadruplet induction (VRd: bortezomib + lenalidomide + dexamethasone; D-VRd: with daratumumab). Lenalidomide maintenance 10 mg for 21 days of 28 after autologous transplant doubles progression-free survival (CALGB 100104). In relapsed myeloma: combinations with carfilzomib, elotuzumab, ixazomib, daratumumab.

Foundation therapy within induction and maintenance regimens.

Sources

  1. AEMPS: Ficha técnica de Lenalidomida (2024)
  2. J Clin Oncol: Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. (2017)
  3. Hemasphere: Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2021)
  4. N Engl J Med: Lenalidomide after stem-cell transplantation for multiple myeloma. (2012)

ICD-10: C90.0 · ICD-11: 2A83.1

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Anti-aging and longevity

Not recommended

Lenalidomide is an immunomodulatory drug, a thalidomide derivative. It is prescribed for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma (AEMPS Ficha Técnica, US REMS program). In alt-anti-aging circles, lenalidomide is occasionally promoted as an immune modulator for anti-aging. In healthy adults, no clinical studies of such use exist, and such prescription is extremely dangerous. The drug has a catastrophic risk profile: teratogenicity (thalidomide derivative, severe birth defects, boxed warning, mandatory REMS program with dual contraception), severe myelosuppression (neutropenia, thrombocytopenia), thromboembolic events (deep vein thrombosis, pulmonary embolism), and secondary malignancies. If lenalidomide was recommended to a healthy person, seek a second opinion immediately; this prescription is life-threatening.

Sources

  1. AEMPS: Ficha técnica de Lenalidomida (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Binds cereblon (CRBN) in the E3 ubiquitin ligase complex, leading to ubiquitination and degradation of transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). This causes direct myeloma cell apoptosis, T- and NK-cell activation, and tumor microenvironment angiogenesis inhibition. Compared with thalidomide, greater myeloma activity and less neurotoxicity, but comparable teratogenic risk.

Safety

Boxed warning

FDA boxed warning: embryo-fetal toxicity (teratogenicity – cannot be taken in pregnancy or by men without reliable contraception – transmits via semen); thromboembolic events (increased VTE risk); severe myelosuppression (neutropenia, thrombocytopenia).

Contraindications

  • Lenalidomide hypersensitivity
  • Pregnancy – absolute contraindication
  • Women of reproductive age outside the Revlimid REMS program
  • Severe renal impairment without dose adjustment
  • Age under 18

Serious adverse effects

  • Severe teratogenicity (causes phocomelia and other limb defects like thalidomide)
  • Venous thromboembolism and myocardial infarction
  • Severe myelosuppression with fatal infections
  • Second primary malignancies (acute myeloid leukemia, myelodysplastic syndromes) with long-term maintenance
  • Severe cutaneous reactions (Stevens–Johnson, DRESS, toxic epidermal necrolysis)
  • Acute liver failure
  • Tumor lysis syndrome
  • Tumor flare reactions

Common adverse effects

  • Fatigue and weakness
  • Neutropenia and thrombocytopenia
  • Diarrhea or constipation
  • Rash
  • Muscle cramps
  • Nausea
  • Insomnia

Pregnancy: can you take Lenalidomide?

Absolute contraindication. Women of reproductive age: two contraception forms from 4 weeks before start, during therapy, and 4 weeks after. Men: barrier method from start and 4 weeks after.

Breastfeeding: can you take Lenalidomide?

Contraindicated during lactation.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Monitoring

Revlimid REMS program is mandatory: monthly pregnancy confirmations in women of reproductive age (test within 24 hours of start and every 4 weeks), two contraception forms in men and women, restricted distribution through certified pharmacies. Thromboprophylaxis (aspirin, low-molecular-weight heparin, or rivaroxaban) is mandatory – VTE risk on lenalidomide + dexamethasone reaches 10–14% without prophylaxis. Monitor CBC (neutropenia, thrombocytopenia) and renal function.
Label mentions7 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Moderateanticonceptivos hormonalesclass named in the label
    «Anticoncepción: Debido al riesgo aumentado de tromboembolismo venoso en pacientes con mieloma múltiple que toman lenalidomida en terapia combinada, y en menor medida en pacientes con mieloma múltiple…»

    AEMPS, section 4.4 · Open on CIMA

  • ModerateDigoxin
    «Digoxina: La administración concomitante de 10 mg una vez al día de lenalidomida incrementó la exposición plasmática de digoxina (0,5 mg, dosis única) en un 14 %, con un IC (intervalo de confianza)…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateDigoxin
    «DRUG INTERACTIONS: Digoxin: Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant lenalidomide capsules therapy ( 7.1 ).»

    FDA, section 7 · Open on DailyMed

  • Moderateestatinasclass named in the label
    «Estatinas: Cuando se administran estatinas con lenalidomida se produce un aumento del riesgo de rabdomiólisis, que puede ser simplemente aditivo. Se justifica un aumento en la monitorización clínica…»

    AEMPS, section 4.5 · Open on CIMA

  • ModerateWarfarin
    «Warfarina: La administración concomitante de dosis múltiples de 10 mg de lenalidomida no tuvo ningún efecto sobre la farmacocinética a dosis única de R-warfarina y S-warfarina. La administración…»

    AEMPS, section 4.5 · Open on CIMA

  • Quinidine
    «Interacciones con inhibidores de la glicoproteína P (Gp-P): In vitro , lenalidomida es un sustrato de la Gp-P, pero no es un inhibidor de la Gp-P. La administración concomitante de dosis múltiples…»

    AEMPS, section 4.5 · Open on CIMA

From other drugs’ labels

  • ModeratePravastatin
    «Lenalidomida: Existe un aumento del riesgo de rabdomiolisis cuando se combina la administración de estatinas con lenalidomida. Se debe reforzar el control clínico y biológico especialmente durante…»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Lenalidomide used for?

Lenalidomide is evaluated for the following indications with varying evidence strength: Multiple myeloma (evidence tier A), Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Lenalidomide?

Common side effects of Lenalidomide (≥ 1 in 100): Fatigue and weakness, Neutropenia and thrombocytopenia, Diarrhea or constipation, Rash, Muscle cramps, Nausea. See the Safety section for uncommon and serious reactions.

Is Lenalidomide safe during pregnancy?

Absolute contraindication. Women of reproductive age: two contraception forms from 4 weeks before start, during therapy, and 4 weeks after. Men: barrier method from start and 4 weeks after.

Is Lenalidomide compatible with breastfeeding?

Contraindicated during lactation.

Who should not take Lenalidomide?

Lenalidomide is contraindicated in: Lenalidomide hypersensitivity; Pregnancy – absolute contraindication; Women of reproductive age outside the Revlimid REMS program; Severe renal impairment without dose adjustment; Age under 18. Full list in the Safety section.

Does Lenalidomide carry an FDA boxed warning?

FDA boxed warning: embryo-fetal toxicity (teratogenicity – cannot be taken in pregnancy or by men without reliable contraception – transmits via semen); thromboembolic events (increased VTE risk); severe myelosuppression (neutropenia, thrombocytopenia).

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Mycophenolate mofetil, Pirfenidone, Pomalidomide, Sirolimus, Adalimumab, Ciclosporin, Tacrolimus, Ustekinumab